Earnings Week Puts Options Market on Edge
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Big Tech earnings are dominating options sentiment this week. AMZN, GOOGL and MSFT all report in the days ahead. Traders are pricing in moves across the board.
Defensive positioning has jumped ahead of the prints. RIVN options are drawing particular attention. The EV maker reports Tuesday against a well-funded short case, making both calls and puts expensive. SOFI shorts sit near a one-year high two days before its own print, a setup that tends to lift put premiums sharply.
CNC carries the highest 7-day options score in the ORTEX screener among large-caps. The health insurer is up 73% year-to-date and reports Q3 results shortly. Elevated RSI of 65.8 alongside a near-perfect ORTEX stock score of 94 suggests the options market is repricing both upside chases and hedges simultaneously.
Taiwan export orders hit a record high in September, the largest since 1984 according to ORTEX Alt Data. That data backs bullish calls in the semiconductor supply chain, where names like INTC face key results this week.
Separately, the ORTEX Index Rebalance Radar flags PCVX as the sharpest swing trade in the current Russell review cycle. Vaxcyte sits within 0.5% of both the Russell 2000 exit line and Russell 1000 entry line simultaneously. A deletion would force $1.2B of selling. That binary outcome is exactly the kind of event that attracts aggressive options bets in the days before the 30 October rank date.
Canada's CPI annual rate rose to 3.1% in September, the highest in two years per ORTEX Alt Data. That adds a macro hedge overlay to broader market puts heading into weekend risk.
Stocks in this article
How this article was generated
- Generated
- 24 Oct 2026, 04:41
- Prompt version
- v1.0
- Data sources
- Options flowORTEX Alpha signalsAlt DataIndex Rebalance
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.